Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.

Primo N Lara, Richard J Bold, Philip Mack, Angela M. Davies, Paul H. Gumerlock, David R Gandara

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Small-cell lung cancer (SCLC) is a tobacco-related malignancy that usually presents in an extensive and therefore incurable stage. Although initially sensitive to platinum agent-based therapy, SCLC rapidly becomes refractory to chemotherapy, leading to disease recurrence and ultimately patient death. Treatment options following failure of first-line platinum agent-based therapy are limited. Small-cell lung cancer is characterized by molecular aberrancies such as overexpression of the antiapoptotic protein Bcl-2, which is regulated in part by the inhibitory IkappaB, a target of the ubiquitin-proteasome degradative pathway. Bortezomib is a proteasome inhibitor that can decrease Bcl-2 expression through diminished IkappaB degradation. Efforts to promote apoptosis in SCLC through the integration of bortezomib into therapy are under way.

Original languageEnglish (US)
JournalClinical lung cancer.
Volume7 Suppl 2
StatePublished - Oct 2005

Fingerprint

Small Cell Lung Carcinoma
Proteasome Endopeptidase Complex
Platinum
Proteasome Inhibitors
Therapeutics
Ubiquitin
Tobacco
Apoptosis
Recurrence
Drug Therapy
Neoplasms
Proteins
Bortezomib

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

Proteasome inhibition in small-cell lung cancer : preclinical rationale and clinical applications. / Lara, Primo N; Bold, Richard J; Mack, Philip; Davies, Angela M.; Gumerlock, Paul H.; Gandara, David R.

In: Clinical lung cancer., Vol. 7 Suppl 2, 10.2005.

Research output: Contribution to journalArticle

@article{dee5796a6ebd42b693d86e374b3c10d0,
title = "Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.",
abstract = "Small-cell lung cancer (SCLC) is a tobacco-related malignancy that usually presents in an extensive and therefore incurable stage. Although initially sensitive to platinum agent-based therapy, SCLC rapidly becomes refractory to chemotherapy, leading to disease recurrence and ultimately patient death. Treatment options following failure of first-line platinum agent-based therapy are limited. Small-cell lung cancer is characterized by molecular aberrancies such as overexpression of the antiapoptotic protein Bcl-2, which is regulated in part by the inhibitory IkappaB, a target of the ubiquitin-proteasome degradative pathway. Bortezomib is a proteasome inhibitor that can decrease Bcl-2 expression through diminished IkappaB degradation. Efforts to promote apoptosis in SCLC through the integration of bortezomib into therapy are under way.",
author = "Lara, {Primo N} and Bold, {Richard J} and Philip Mack and Davies, {Angela M.} and Gumerlock, {Paul H.} and Gandara, {David R}",
year = "2005",
month = "10",
language = "English (US)",
volume = "7 Suppl 2",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",

}

TY - JOUR

T1 - Proteasome inhibition in small-cell lung cancer

T2 - preclinical rationale and clinical applications.

AU - Lara, Primo N

AU - Bold, Richard J

AU - Mack, Philip

AU - Davies, Angela M.

AU - Gumerlock, Paul H.

AU - Gandara, David R

PY - 2005/10

Y1 - 2005/10

N2 - Small-cell lung cancer (SCLC) is a tobacco-related malignancy that usually presents in an extensive and therefore incurable stage. Although initially sensitive to platinum agent-based therapy, SCLC rapidly becomes refractory to chemotherapy, leading to disease recurrence and ultimately patient death. Treatment options following failure of first-line platinum agent-based therapy are limited. Small-cell lung cancer is characterized by molecular aberrancies such as overexpression of the antiapoptotic protein Bcl-2, which is regulated in part by the inhibitory IkappaB, a target of the ubiquitin-proteasome degradative pathway. Bortezomib is a proteasome inhibitor that can decrease Bcl-2 expression through diminished IkappaB degradation. Efforts to promote apoptosis in SCLC through the integration of bortezomib into therapy are under way.

AB - Small-cell lung cancer (SCLC) is a tobacco-related malignancy that usually presents in an extensive and therefore incurable stage. Although initially sensitive to platinum agent-based therapy, SCLC rapidly becomes refractory to chemotherapy, leading to disease recurrence and ultimately patient death. Treatment options following failure of first-line platinum agent-based therapy are limited. Small-cell lung cancer is characterized by molecular aberrancies such as overexpression of the antiapoptotic protein Bcl-2, which is regulated in part by the inhibitory IkappaB, a target of the ubiquitin-proteasome degradative pathway. Bortezomib is a proteasome inhibitor that can decrease Bcl-2 expression through diminished IkappaB degradation. Efforts to promote apoptosis in SCLC through the integration of bortezomib into therapy are under way.

UR - http://www.scopus.com/inward/record.url?scp=33644663463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644663463&partnerID=8YFLogxK

M3 - Article

C2 - 16250931

AN - SCOPUS:33644663463

VL - 7 Suppl 2

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

ER -